Roche Holding AG (RHHBF)
| Market Cap | 367.47B +28.8% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 24.06 |
| Forward PE | 17.87 |
| Dividend | 12.41 (2.71%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 230 |
| Open | 435.00 |
| Previous Close | 458.47 |
| Day's Range | 435.00 - 458.47 |
| 52-Week Range | 301.27 - 514.08 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 21, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Why pharma giant Roche is putting German investments on hold
Germany’s bid to revive its struggling economy faces a fresh setback as a major pharmaceutical player raises concerns over the country’s business climate.
Hansoh Pharma (HNSPF) Partners with Roche in $14B+ Cancer Drug Collaboration
Hansoh Pharma (HNSPF) Partners with Roche in $14B+ Cancer Drug Collaboration
Roche (RHHBY) Halts Investment Plans in Germany Amid Healthcare Reform Uncertainty
Roche (RHHBY) Halts Investment Plans in Germany Amid Healthcare Reform Uncertainty
Hansoh Pharmaceutical enters collaboration, license agreement with Roche
Hansoh Pharmaceutical Group (HNSPF) announces that it has entered into a strategic collaboration and license agreement with Roche (RHHBY). This agreement marks the second collaboration between the two...
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
China's Hansoh Pharmaceutical said on Monday its units have entered into a collaboration and licensing deal with Roche potentially worth more than $15 billion, covering a portfolio of antibody-drug co...
Roche To Present New Phase 3 Divarasib, Giredestrant, Tam-Peli Data At ESMO 2026
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that it will present new data from the Phase III Krascendo 1 trial evaluating divarasib in previously treated advanced G12C-mutate...
Roche moves future Germany investments 'on hold'
Swiss drugmaker Roche is reviewing all future investments in Germany over healthcare cost-cutting policies, the company's Germany chief said in an interview with newspaper Welt that was published on M...
Roche to unveil lung, breast cancer data at ESMO 2026
Roche said on Monday it will present new late-stage trial results at the ESMO 2026 cancer meeting in Madrid, including data showing its lung cancer drug divarasib worked better than current KRA...
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech to present new data at ESMO across oncology portfolio including positive Phase III Krascendo 1 data in lung cancer.
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical...
Genentech announces FDA approval of Enspryng for the treatment of TED
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Enspryng for the treatment of adults with thyroid eye disease, or TED, providing patients with the first and…
FDA Approves Roche's Enspryng For Thyroid Eye Disease
(RTTNews) - On Friday, Roche Holding AG (RHHBY) announced that the U.S. Food and Drug Administration approved Enspryng for adults with thyroid eye disease, making it the first at-home subcutaneous tre...
Roche Announces FDA Approval Of Enspryng
(RTTNews) - Roche (RO.SW, ROG.SW) announced the FDA has approved Enspryng for the treatment of adults with thyroid eye disease. Enspryng can be administered by a person living with TED or a caregiver ...
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Basel, 16 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab) for the treatment of adults with thyr...
Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy
Roche's Genentech has settled a US lawsuit against Indian biopharmaceutical company Biocon over its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta, Biocon said Wednesday.
Rona Therapeutics Licenses Obesity Drug Candidate To Roche In Deal Worth Up To $1.16 Billion
(RTTNews) - Rona Therapeutics has entered into a global licensing agreement with Roche (RHHBY) for an investigational RNA interface (RNAi) therapy targeting activin receptor-like kinase 7 (ALK7), a ge...
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday.
Nurix Swings To Profit In Q3 As Roche Deal Drives Revenue Surge
(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, reported third-quarter 2026 financial results alongside updates on its clinical pipeline and business collabora...
Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue
(RTTNews) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period, primarily reflecting a major ...
Roche (RHHBY) Adds China Discovery Optionality as Pipeline Risk Stays in Focus
Roche Holding Ltd. (RHHBY) is leaning further into external innovation at a time when its core pharmaceutical business is still... The post Roche (RHHBY) Adds China Discovery Optionality as Pipeline R...
Roche’s Genentech announces new one-year data from Phase III Meerkat, Sandcat
Genentech, a member of the Roche (RHHBY) Group, announced new one-year data from the Phase III Meerkat and Sandcat studies evaluating investigational vamikibart compared with a sham procedure that mim...
Roche's Vamikibart Shows Promise in Vision Treatment, RHHBY Dividend Remains Attractive
Roche's Vamikibart Shows Promise in Vision Treatment, RHHBY Dividend Remains Attractive
Roche's Vamikibart Shows One-Year Vision Benefits In Uveitic Macular Edema; FDA Accepts Filing
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced positive one-year results from its Phase III MEERKAT and SANDCAT studies evaluating investigational therapy vamikibart in adults with uveitic macular...